Lumida
/IOSP
⌘K
Innospec Inc

Innospec Inc

IOSP
$84.25USD↓-1.42%-1.21 today

MARKET CAP

2.1B

P/E (TTM)

17.1x

FWD P/E

14.5x

DAY RANGE

$84 – $87

52W RANGE

$66
$92

AI Summary

Stalk
StalkMedium

Despite a healthy Stage 2 advancing regime marked by higher highs and higher lows, price is currently extended above rising short-term EMAs and in extreme overbought territory, reducing immediate entry appeal. The medium-term bias remains bullish, but short-term timing is unfavorable. We will stalk for pullbacks into rising 9/20 EMAs or the 50 DMA, seeking support and renewed momentum before engaging.

  • ↑Fuel specialties segment revenue grew to $181.6M, +7% YoY with strong volumes and pricing.
  • ↑Repurchased 90,000 shares for $6.2M and increased dividend 10% to $0.92/share.
  • ↓Performance chemicals volumes declined 9% due to winter‐storm shutdowns, squeezing segment margins.
Full analysis →

The case for & against

Bull & Bear analysis

Bullish

Innospec (NASDAQ: IOSP) is a prominent player in the specialty chemicals sector, primarily focusing on performance chemicals, fuel specialties, and oilfield services. The company has established a diversified portfolio that allows it to navigate the complexities of market dynamics while emphasizing operational efficiency and sustainable growth. With solid demand in fuel specialties and ongoing innovations, Innospec seeks to leverage its strengths to achieve performance improvements across its segments.

Bull says

  • ↑Fuel specialties segment revenue grew to $181.6M, +7% YoY with strong volumes and pricing.
  • ↑Repurchased 90,000 shares for $6.2M and increased dividend 10% to $0.92/share.
  • ↑Cash balance of $289.1M with zero debt supports M&A and shareholder returns.
  • ↑Management forecasts sequential improvements in operational income and margins.
  • ↑High earnings yield, positive analyst revisions, and 2.23% dividend yield bolster valuation appeal.
  • ↑Ongoing product introductions and process optimizations drive market share gains.

Bear says

  • ↓Performance chemicals volumes declined 9% due to winter‐storm shutdowns, squeezing segment margins.
  • ↓Gross margin dipped to 27.3% from 28.4% YoY, reflecting cost pressures and inflation.
  • ↓Net income slid to $30.4M and adjusted EBITDA dropped to $43.7M in Q1.
  • ↓P/E ratio of 17.7 and PEG of 2.3 imply valuation risks amid slow growth.
  • ↓High short interest and weak profitability factors signal investor skepticism.
  • ↓Geopolitical tensions and rising raw‐material costs threaten future margin stability.

Investment themes with IOSP

High Dividend Yield↑ +0.32%

Companies paying above-average dividends

AVGO · JPM · XOM

Earnings Call · Q1 2026 · Mgmt. Guidance

Updated 05-10-2026neutral

Transcript signals

Bull points

  • £181.6 million, up 7% from the £170.3 million reported a year ago, driven by a 10% increase in volumes and a favourable currency impact of 6%.
  • Operating income of 5.6 million increased 37% from 4.1 million a year ago, indicating strong performance in this segment.
  • In the first quarter, we bought about 90,000 shares at a cost of $6.2 million.

Bear points

  • 1.1 percentage points from last year to 27.3%.
  • Adjusted EBITDA for the quarter was 43.7 million compared to 54 million last year, indicating a decline in profitability.
  • 9% in performance chemicals were noted, offsetting some of the revenue growth achieved through price mix and currency impacts, showing challenges in demand.
Read full transcript analysis ›